Dana Fontenot, APRN
Family · Alexandria, LANPI 1174819668
Payments from drug & device makers
Across 190 payments — averaging $25.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Novo Nordisk$531
- Lilly USA, LLC$444
- AbbVie$380
- AstraZeneca$356
- GSK$211
- plus $1K from 27 others
What the payments were for
- Travel & lodging$1,46831%
- Food & beverage$3,29869%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 14 | $1,684 |
| Novo Nordisk | 46 | $531 |
| Lilly USA, LLC | 19 | $444 |
| AbbVie | 18 | $380 |
| AstraZeneca | 12 | $356 |
| GSK | 12 | $211 |
| Amgen | 9 | $175 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $123 |
| Pfizer | 6 | $107 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $80 |
| Abbott | 5 | $72 |
| Xeris Pharmaceuticals, Inc. | 4 | $66 |
| Dexcom, Inc. | 3 | $59 |
| Biohaven Pharmaceuticals, Inc. | 3 | $43 |
| Sunovion Pharmaceuticals Inc. | 3 | $41 |
| Boehringer Ingelheim | 2 | $39 |
| Corcept Therapeutics | 2 | $36 |
| Astellas Pharma US Inc | 2 | $30 |
| Johnson & Johnson | 2 | $29 |
| Sumitomo Pharma America, Inc. | 1 | $28 |
| Eisai Inc. | 2 | $25 |
| Neurocrine Biosciences, Inc. | 1 | $23 |
| Viiv Healthcare Company | 1 | $21 |
| Idorsia Pharmaceuticals US Inc | 1 | $21 |
| Gilead | 1 | $19 |
| Cequr Corporation | 1 | $18 |
| Bayer | 1 | $18 |
| Bausch Health US, LLC | 1 | $17 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Novartis | 1 | $15 |
| Endo Pharmaceuticals Inc. | 1 | $12 |
| Arbor Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 770G$1,321
- AIRSUPRA$135
- MOUNJARO$100
How this compares
$4,766 in reported general payments places this provider in the 90th percentile of 3,610 family providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 74 | $122,857 |
| OzempicSemaglutide | 45 | $41,767 |
| DescovyEmtricitabine/Tenofov Alafenam | 16 | $34,088 |
| JardianceEmpagliflozin | 19 | $33,404 |
| EliquisApixaban | 28 | $30,337 |
| TrulicityDulaglutide | 20 | $20,702 |
| RybelsusSemaglutide | 19 | $19,404 |
| FarxigaDapagliflozin Propanediol | 16 | $16,152 |
| Tresiba Flextouch U-200Insulin Degludec | 17 | $15,802 |
| VeozahFezolinetant | 12 | $12,385 |
| JanumetSitagliptin Phos/Metformin Hcl | 15 | $12,274 |
| LinzessLinaclotide | 21 | $11,295 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $7,771 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 11 | $5,418 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 61 | $1,978 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $444 | $143,55894 claims |
| Novo NordiskOzempic, Rybelsus | $531 | $61,17164 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $39 | $38,82230 claims |
| GileadDescovy | $19 | $34,08816 claims |
| PfizerEliquis | $107 | $30,33728 claims |
| AstraZenecaFarxiga | $356 | $16,15216 claims |
| AbbVieLinzess, Synthroid | $380 | $12,88844 claims |
| Astellas Pharma US IncVeozah | $30 | $12,38512 claims |
| GSKBreo Ellipta | $211 | $7,77119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,610 family providers in Louisiana.
Other family in Alexandria
- Kimberly RaoAlexandria$90K
- Lacey LemoineAlexandria$25K
- Kimberly LabordeAlexandria$14K
- Rebecca EzellSlidell$268K
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Ashlea HillRuston$169K
- Brittany MillerVille Platte$158K
- Ryanne ClarkeGretna$123K
- Elidia DewittBaton Rouge$108K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.